Eli Gilboa

A multi-pronged approach to cancer immunotherapy using nucleic acid-based drug and drug delivery platforms.

The current research in the Gilboa lab is focused on developing a combination of complementary and synergistic cell-targeted immune stimulatory strategies using short nucleic acid based therapeutic agents, such as siRNAs or microRNAs, conjugated to cell-specific oligonucleotide aptamer-based targeting ligands, to enhance the antigenicity of disseminated tumor lesions, promote immune memory, target immune modulation to the tumor lesion and enhance the uptake of tumor antigens by the professional antigen presenting system.